



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Tucotuzumab

| | |
|------------------|---|
| Cat. No.: | HY-P99328 |
| CAS No.: | 339986-90-2 |
| Target: | Interleukin Related |
| Pathway: | Immunology/Inflammation |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |

BIOLOGICAL ACTIVITY

| | | |
|--------------------|---|--|
| Description | Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule ^[1] . | |
| In Vitro | Tucotuzumab targets tumors and stimulate an antitumor immune response via IL-2 responsive immune cells, as well as immune cells via their Fc receptor ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| In Vivo | Tucotuzumab (75 µg; intratumoral injection; 5 daily of 15 µg (total dose of 75 µg), each in 50 µL PBS; on days 10 and 14) results in significantly greater tumor growth suppression and enhances survival ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |
| | Animal Model: | Female Balb/c mice bearing CT26-KS colon adenocarcinoma ^[1] |
| | Dosage: | 75 µg |
| | Administration: | Intratumoral injection; 5 daily of 15 µg (total dose of 75 µg), each in 50 µL PBS; on days 10 and 14 |
| | Result: | Resulted in significantly greater tumor growth suppression and enhanced survival. |

REFERENCES

[1]. Erik E Johnson, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 1;15(15):4875-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA